The safety of rofecoxib

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Drug Safety

Background:

• Selective COX-2 inhibitors, like rofecoxib, were developed to offer improved gastrointestinal safety over traditional NSAIDs.
• The Vioxx GI Outcomes Research trial confirmed rofecoxib's gastrointestinal benefits but highlighted potential cardiovascular risks.
• Subsequent epidemiological studies suggested an increased risk of cardiovascular events associated with rofecoxib use.

Purpose of the Study:

• To evaluate the cardiovascular safety of rofecoxib in comparison to conventional NSAIDs.
• To explore potential pathogenic mechanisms underlying the increased cardiovascular risk observed with rofecoxib.
• To assess the scientific justification for rofecoxib's market withdrawal and its implications for the COX-2 inhibitor class.

Main Methods:

• Review of clinical trial data, including the Vioxx GI Outcomes Research trial.
• Analysis of epidemiological and case-control studies investigating rofecoxib and cardiovascular events.
• Examination of proposed pathogenic mechanisms, such as prothrombotic state, sodium retention, and increased blood pressure.

Main Results:

• Rofecoxib demonstrated superior gastrointestinal safety compared to NSAIDs.
• Evidence accumulated suggesting an association between rofecoxib and an elevated risk of cardiovascular events.
• Pathogenic mechanisms proposed include prothrombotic effects, sodium retention, and hypertension.

Conclusions:

• Despite gastrointestinal benefits, rofecoxib's cardiovascular risks led to its market withdrawal.
• The withdrawal raises questions about the scientific basis for removing rofecoxib versus label modification.
• The market withdrawal poses a significant challenge to the entire class of selective COX-2 inhibitors, necessitating a re-evaluation of their risk-benefit profiles.